Table 2. Regorafenib‐related adverse events reported in ≥5% of patients (n = 1,227).

^aHFSR, hand‐foot skin reaction; equivalent to hand‐and‐foot syndrome in MedDRA ver 19.0.

^bIncludes all liver‐relevant events and significant changes in hepatic laboratory values.